Researchers at the University of Georgia and Sanofi Pasteur, a multinational pharmaceutical company announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.

Using a technique called Computationally Optimized Broadly Reactive Antigen, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.

Sanofi Pasteur and UGA researchers are set to present their data tomorrow, March 30, at the World Vaccine Congress located in Washington, D.C.